title: [A patient with advanced remnant gastric cancer responding completely to S-1 monotherapy].
abstract: A 74-year-old man with anemia visited our hospital. When he was 42 years old, he was diagnosed with duodenal ulcer and underwent gastrectomy with Billroth II construction. A gastrointestinal endoscopic examination revealed an ulcerative lesion at the remnant stomach, and the pathological examination of the biopsy specimen showed moderate to poorly differentiated adenocarcinoma. Abdominal CT scan revealed liver and para-aortic lymphnode metastases. He received daily oral administration of S-1 at a dose of 100 mg/body, bid, 4 weeks on and 2 weeks off. After 4 courses of S-1, CT scan showed a complete response of the liver and also para-aortic lymphnode metastasis. He underwent total remnant gastrectomy with D2 dissection. Histological examination revealed no residual cancer cells in the surgically removed stomach and lymphnode, and he was diagnosed a complete pathological response (Grade 3). He refused adjuvant S-1, but is in good health without recurrence 2 years after the operation.
authors.affiliation: Dept. of Surgery, Sonoda Dai-ichi Hospital, Surugadai Nihon University Hospital, Japan.
authors.forename: Asuo
authors.initials: A
authors.lastname: Okaniwa
authors.forename: Isao
authors.initials: I
authors.lastname: Murayama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hayashi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kasakura
authors.forename: Noriko
authors.initials: N
authors.lastname: Kinukawa
authors.forename: Norimichi
authors.initials: N
authors.lastname: Nemoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Fujii
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D018530:Gastric Stump / Q000473:pathology*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid